|
Definition |
All patients who receive docetaxel-based chemotherapy for CRPC will progress, thus, there have been many clinical trials investigating the role of salvage chemotherapy. Several groups have used second-line intermittent docetaxel re-treatment in patients who had clearly responded to first-line docetaxel. In general, a PSA response can be achieved in about 60% of patients with a median time to progression of about 6 months, while treatment-associated toxicity is minimal and similar to that of first-line docetaxel.
|